DIRS.INFO The most relevant business & tech news

☆ New Ultrasound Therapy Could Help Treat Alzheimer’s, Cancer
▼ + stars: | 2023-07-31 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/ultrasound-therapy-alzheimers-cancer-treatment-862f1390

Persons: Dow Jones

☆ Why You Can’t Find Wegovy, the Weight-Loss Drug
▼ + stars: | 2022-12-04 | by ( Peter Loftus | Denise Roland | ) www.wsj.com time to read: 1 min

Wegovy is among a new class of drugs regulators have approved to lower the weight of people who are obese, a goal long sought by doctors and patients. Novo Nordisk A/S flubbed the launch of its buzzy new weight-loss drug Wegovy, missing out on hundreds of millions of dollars in sales and squandering a head start before a rival could begin selling a competing product. Wegovy is among a new class of drugs that health regulators have approved to cut the weight of people who are obese, a goal long sought by doctors and patients. Elon Musk tweeted about Wegovy in October. And a related drug for diabetes, Ozempic, is a hot topic in Hollywood among celebrities seeking to stay thin, according to doctors.

☆ Nestlé May Shed Peanut Allergy Treatment as Sales Disappoint
▼ + stars: | 2022-11-29 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

Palforzia exposes patients to gradually higher doses of peanut powder. The treatment requires visiting a doctor every two weeks for four to five months. The world’s only approved peanut allergy drug has so far proved a flop. Nestlé SA said Tuesday it would explore strategic options for the treatment, effectively putting the drug up for sale, following lower-than-expected demand from doctors and patients. The move comes just two years after the packaged-food giant agreed to buy the developer of the drug, called Palforzia, in a $2.6 billion deal.

☆ Alzheimer’s Drug From Roche Fails in Late-Stage Trials
▼ + stars: | 2022-11-14 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

An experimental Alzheimer’s drug from Roche Holding AG failed to significantly slow cognitive decline in long-awaited trials, the latest in a long line of setbacks for a field that has seen little progress in decades. The drug, called gantenerumab, slightly reduced cognitive decline in people with early Alzheimer’s compared with a placebo across two large and lengthy trials, but the difference wasn’t statistically significant, Roche said Monday. The trials, which lasted more than two years and involved nearly 2,000 participants, compared scores of cognition and function in areas such as memory, orientation and problem-solving.

☆ New Antibiotic for Urinary-Tract Infections Found Effective in Trials
▼ + stars: | 2022-11-03 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

GSK said the new drug, called gepotidacin, was effective in two large clinical trials spanning around 3,000 patients. GSK PLC said its experimental treatment for uncomplicated urinary-tract infections was effective in two large clinical trials, paving the way for what could be the first new oral antibiotic for the common ailment in more than two decades. Around half of all women have suffered a urinary-tract infection, or UTI, at least once, and recurrence is common, according to studies. UTIs are typically treated with antibiotics, but some bacteria have developed resistance to existing drugs, creating a need for new treatment options.

☆ With Energy Crisis Looming, U.K. Weather Agency Is Set to Say How Cold Britain’s Winter Could Get
▼ + stars: | 2022-10-29 | by ( Denise Roland | Joe Wallace | ) www.wsj.com time to read: 1 min

The U.K. Meteorological Office’s updated three-month weather outlook is due next week. LONDON—The national weather service here makes a big call Monday: Will Britain’s winter be mild and wet, or cold and dry? The U.K. Meteorological Office is poised to update its seasonal winter outlook next week. The routine report is typically fodder for weather junkies and ski resorts. Amid Europe’s energy crisis, the release is attracting a much wider audience.

☆ Philips to Cut 4,000 Jobs as Big Recall, Supply Snags Hit Earnings
▼ + stars: | 2022-10-24 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

Royal Philips NV said it would cut 4,000 jobs in a bid to turn around its embattled business, as it grapples with supply-chain challenges and the fallout from a huge recall of devices used to treat sleep apnea. The Dutch healthcare conglomerate said Monday that the job cuts, which amount to about 5% of its 80,000-strong workforce, would simplify its operations and save about 300 million euros, equivalent to about $296 million, a year.

☆ Monkeypox Researchers Recommend Vigilance as Cases Decline
▼ + stars: | 2022-10-21 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

As a global outbreak of monkeypox loses steam, disease researchers said they need a better understanding of how the virus spreads, and how well vaccination protects against it to predict whether it could come roaring back. A global outbreak that gained momentum in May spread the virus much farther than it had been found previously. The virus might have reached new animal hosts, increasing the risk of future outbreaks, said epidemiologists and infectious-disease specialists. The extent to which vaccination has protected the most at-risk people from catching monkeypox is unknown.

☆ GSK Poised for Pfizer Battle in RSV Vaccine Market
▼ + stars: | 2022-10-13 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

LONDON– GSK PLC said its experimental vaccine against respiratory syncytial virus sharply reduced the risk of disease in a key trial, paving the way for a contest with Pfizer Inc. in what the companies expect to be a lucrative market. Respiratory syncytial virus, or RSV, is a common virus that proves deadly for some 14,000 older adults in the U.S. every year. Although identified decades ago, there are no approved vaccines against the virus, which in most people causes cold-like symptoms but can lead to more severe disease affecting the lungs in young babies and older adults. Now, two shots are jostling to be the first to a market that analysts estimate could be worth around $5 billion a year.

☆ Philips to Take $1.3 Billion Write-Down on Sleep-Apnea Business
▼ + stars: | 2022-10-12 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

Royal Philips Chief Financial Officer Abhijit Bhattacharya said the company couldn’t speculate on the outcome, content or timing of any agreement with the Justice Department over a potential settlement. Royal Philips NV said it would write down the value of its sleep and respiratory care business by €1.3 billion, equivalent to $1.26 billion, as it grapples with the fallout from a huge recall of devices used to treat sleep apnea. The update came Wednesday as the Dutch healthcare conglomerate warned that worse-than-expected supply-chain disruptions would hurt third-quarter sales and profit. Philips said it expected third-quarter sales to decline 5% to €4.3 billion and for adjusted earnings before interest, taxes and amortization of around €210 million, sharply down from €512 million a year earlier. The company is set to report full earnings later this month.

☆ AstraZeneca Looks to Cancer, RSV Drugs for Growth as Covid-Vaccine Demand Wanes
▼ + stars: | 2022-10-11 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

AstraZeneca PLC produced one of the world’s most widely used Covid-19 vaccines. As demand for the shot ebbs, the company is betting on tackling breast cancer and a different respiratory virus. After the pandemic hit, the drugmaker poured resources into fighting Covid-19. It produced a vaccine and a drug, named Evusheld. The vaccine didn’t generate a profit, however, and its rollout faced a string of challenges including confusion over trial data, concerns about a rare side effect and delayed deliveries.

☆ AstraZeneca Drops Plan to Sell Covid-19 Vaccine in U.S.
▼ + stars: | 2021-03-10 | by ( Denise Roland | ) www.wsj.com time to read: 1 min

AstraZeneca PLC said it had dropped plans to submit its Covid-19 vaccine to the Food and Drug Administration for approval, ending a long-running ambition to eventually sell the shot in the U.S. despite initial setbacks. The Cambridge, England-based pharmaceutical company said Thursday that there would likely be a lack of demand in the U.S., where it said primary vaccination needs had been met. It would continue to focus its efforts on ensuring the availability of the vaccine, called Vaxzevria, elsewhere, including seeking its approval as a booster shot, the company said.

Search resuls for: "Denise Roland"

12 mentions found